Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of ME1111 Solution in Mild to Moderate Onychomycosis
jRCT2080223784Phase 2Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ME1111 in onychomycosis (3 arms), sponsored by Meiji Seika Pharma Co., Ltd. Started Jan 2018; status: completed.
02
Drugs
ME1111
03
Conditions
onychomycosis
Beyond the preview
Go deeper on jRCT2080223784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223784.